2024
Elevated myocardial extracellular volume fraction is associated with the development of conduction pathway defects following transcatheter aortic valve replacement
Feroze R, Kang P, Dallan L, Akula N, Galo J, Yoon S, Ukaigwe A, Filby S, Baeza C, Pelletier M, Rushing G, Rajagopalan S, Al‐Kindi S, Rashid I, Attizzani G. Elevated myocardial extracellular volume fraction is associated with the development of conduction pathway defects following transcatheter aortic valve replacement. Catheterization And Cardiovascular Interventions 2024, 104: 1119-1128. PMID: 38952304, DOI: 10.1002/ccd.31136.Peer-Reviewed Original ResearchMeSH KeywordsAction PotentialsAgedAged, 80 and overAortic ValveAortic Valve StenosisArea Under CurveAtrioventricular BlockBundle-Branch BlockCardiac Pacing, ArtificialFemaleFibrosisHeart Conduction SystemHumansMagnetic Resonance Imaging, CineMaleMyocardiumPacemaker, ArtificialPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsROC CurveTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementCardiac magnetic resonance imagingLate gadolinium enhancementRight bundle branch blockArea under the receiver operating characteristic curveAortic valve replacementReceiver operating curveMyocardial fibrosisPost-TAVRConduction defectsBundle branch blockAssociations of myocardial fibrosisExtracellular volumeConduction diseaseValve replacementGadolinium enhancementPermanent pacemakerConduction abnormalitiesConduction deficitsHeart blockBranch blockRisk of heart blockSeptal late gadolinium enhancementMyocardial extracellular volume fractionBaseline conduction disease
2020
Utility of 90-Day Mortality vs 30-Day Mortality as a Quality Metric for Transcatheter and Surgical Aortic Valve Replacement Outcomes
Hirji S, McGurk S, Kiehm S, Ejiofor J, Val F, Kolkailah A, Berry N, Sobieszczyk P, Pelletier M, Shah P, O’Gara P, Kaneko T. Utility of 90-Day Mortality vs 30-Day Mortality as a Quality Metric for Transcatheter and Surgical Aortic Valve Replacement Outcomes. JAMA Cardiology 2020, 5: 156-165. PMID: 31851293, PMCID: PMC6990722, DOI: 10.1001/jamacardio.2019.4657.Peer-Reviewed Original ResearchConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementSurgical aortic valve replacement proceduresAortic valve replacementHospital performanceEvaluation of hospital performanceValve replacementHospital performance rankingsCohort study analyzed dataMeasure hospital performanceConcomitant coronary artery bypass graftingCoronary artery bypass graftingProcedure-related mortalityOpen-heart proceduresStudy analyzed dataPatient risk profileSurgical aortic valve replacement outcomesTAVR admissionsArtery bypass graftingMedicare beneficiariesMain OutcomesReplacement outcomesOutcome metricsRisk adjustmentBypass graftingRelationship Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes
Hirji S, McCarthy E, Kim D, McGurk S, Ejiofor J, Val F, Kolkailah A, Rosner B, Shook D, Nyman C, Berry N, Sobieszczyk P, Pelletier M, Shah P, O’Gara P, Kaneko T. Relationship Between Hospital Surgical Aortic Valve Replacement Volume and Transcatheter Aortic Valve Replacement Outcomes. JACC Cardiovascular Interventions 2020, 13: 335-343. PMID: 32029250, PMCID: PMC8858441, DOI: 10.1016/j.jcin.2019.09.048.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveClinical CompetenceDatabases, FactualFemaleHeart Valve Prosthesis ImplantationHospitals, High-VolumeHospitals, Low-VolumeHumansMaleMedicareOutcome and Process Assessment, Health CareQuality Indicators, Health CareRisk AssessmentRisk FactorsTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeUnited StatesConceptsTranscatheter aortic valve replacementSurgical aortic valve replacementTranscatheter aortic valve replacement outcomesAortic valve replacementValve replacementConcomitant coronary artery bypass graft surgeryGroup 2Aortic valve replacement volumesGroup 1Group 3Group 4Surgical aortic valve replacement volumeCoronary artery bypass graft surgeryTranscatheter aortic valve replacement procedureArtery bypass graft surgeryAortic valve replacement proceduresYear post-procedureOpen-heart proceduresRisk-adjusted odds ratioMultivariate Cox regressionHeart valve proceduresLow-volume centersValve replacement proceduresTAVR admissionsBypass graft surgery
2019
Cardiac Surgery in Patients With Opioid Use Disorder: An Analysis of 1.7 Million Surgeries
Shah R, Hirji S, Percy E, Landino S, Yazdchi F, Bellavia A, Pelletier M, Shekar P, Kaneko T. Cardiac Surgery in Patients With Opioid Use Disorder: An Analysis of 1.7 Million Surgeries. The Annals Of Thoracic Surgery 2019, 109: 1194-1201. PMID: 31479643, DOI: 10.1016/j.athoracsur.2019.07.041.Peer-Reviewed Original ResearchConceptsOpioid use disorderCardiac surgeryIncreased risk of postoperative morbidityImpact of opioid use disorderRisk of postoperative morbidityOpioid epidemicAssociated with prolonged hospitalizationRisk factorsUse disorderOpioid use disorder statusCoronary artery bypass graftingNon-opioid usersPreoperative risk factorsCardiac surgery patientsPatient's preoperative risk factorsAcute kidney injuryArtery bypass graftingCardiac surgery outcomesIn-hospital mortalityCurrent opioid epidemicLonger hospital lengthImprove overall outcomesHigher hospital costsNational Inpatient SampleValve repairChronic opioid use after coronary bypass surgery
Hirji S, Landino S, Cote C, Lee J, Orhurhu V, Shah R, McGurk S, Kaneko T, Shekar P, Pelletier M. Chronic opioid use after coronary bypass surgery. Journal Of Cardiac Surgery 2019, 34: 67-73. PMID: 30625257, DOI: 10.1111/jocs.13981.Peer-Reviewed Original ResearchConceptsOpioid-exposed patientsCoronary artery bypass graftingOpioid naive patientsChronic opioid useChronic opioid dependenceOpioid dependencePrescribing patternsOpioid useIsolated coronary artery bypass graftingAlternative pain management strategiesTotal dose >Opioid prescribing patternsPain management strategiesArtery bypass graftingCoronary bypass surgeryInvasive surgical proceduresOpioid usageBypass surgeryPain managementBypass graftingSurgical proceduresOpioidOpioid epidemicPatientsMedication usage
2017
Very Early Subclinical Valve Thrombosis After Transcatheter Aortic Valve Replacement
Berry N, Sawlani N, Kim A, Kaneko T, Shah P, Pelletier M, Sobieszczyk P. Very Early Subclinical Valve Thrombosis After Transcatheter Aortic Valve Replacement. Circulation Cardiovascular Interventions 2017, 10 PMID: 29127117, DOI: 10.1161/circinterventions.117.005593.Peer-Reviewed Original ResearchImpact of flow, gradient, and left ventricular function on outcomes after transcatheter aortic valve replacement
Carreras E, Kaneko T, Val F, Pelletier M, Sobieszczyk P, Bhatt D, Shah P. Impact of flow, gradient, and left ventricular function on outcomes after transcatheter aortic valve replacement. Catheterization And Cardiovascular Interventions 2017, 91: 798-805. PMID: 28988432, PMCID: PMC5849510, DOI: 10.1002/ccd.27347.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAortic Valve StenosisBostonFemaleHeart FailureHospital MortalityHumansLength of StayMaleRecovery of FunctionRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexStroke VolumeTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftConceptsTranscatheter aortic valve replacementAortic valve replacementStroke volume indexHeart failureReduced LVEFValve replacementIncreased mortalityOutcomes similar to patientsTranscatheter aortic valve replacement patientsPredictor of 1-year mortalityAssociated with increased mortalityOutcomes of patientsLeft ventricular functionSimilar to patientsReduced EFVentricular functionLVEFClinical factorsWomen's HospitalVolume indexPatientsAssociated with increasesMortalityTranscatheterOutcomesAspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial
Rodés-Cabau J, Masson J, Welsh R, del Blanco B, Pelletier M, Webb J, Al-Qoofi F, Généreux P, Maluenda G, Thoenes M, Paradis J, Chamandi C, Serra V, Dumont E, Côté M. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovascular Interventions 2017, 10: 1357-1365. PMID: 28527771, DOI: 10.1016/j.jcin.2017.04.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAortic ValveAspirinBalloon ValvuloplastyCanadaClopidogrelDrug Therapy, CombinationEarly Termination of Clinical TrialsEuropeFemaleFibrinolytic AgentsHeart Valve ProsthesisHemorrhageHumansIschemic Attack, TransientKaplan-Meier EstimateMaleMyocardial InfarctionPlatelet Aggregation InhibitorsProsthesis DesignRisk FactorsSouth AmericaStrokeThrombosisTiclopidineTime FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementTransient ischemic attackLife-threatening bleedingAortic valve replacementBalloon-expandable valveOccurrence of deathMyocardial infarctionIschemic attackBleeding eventsValve replacementAntithrombotic treatmentClinical trialsLife-threatening bleeding eventsPrevention of ischemic eventsOptimal antithrombotic therapyComposite of deathRandomized clinical trialsPlanned study populationLife-threatening eventsRandomized controlled trialsCompared aspirinPrimary endpointAntithrombotic therapyPost-TAVRAdverse events
2015
Increased Distance From the Tertiary Cardiac Center Is Associated With Worse 30-Day Outcomes After Cardiac Operations
Cote C, Singh S, Yip A, Murray J, MacLeod J, Lutchmedial S, Brown C, Forgie R, Pelletier M, Hassan A. Increased Distance From the Tertiary Cardiac Center Is Associated With Worse 30-Day Outcomes After Cardiac Operations. The Annals Of Thoracic Surgery 2015, 100: 2213-2218. PMID: 26271578, DOI: 10.1016/j.athoracsur.2015.05.058.Peer-Reviewed Original ResearchConceptsTertiary cardiac care centerCardiac operationsCardiac care centerIn-hospitalNonemergent cardiac operationsCare centerRisk of adverse outcomesEffect of driving distanceTertiary cardiac centerIn-hospital outcomesMultivariate logistic regressionCardiac centerRetrospective analysisFollow-upAdverse outcomesPatient groupPatientsStudy populationLogistic regressionCardiovascular carePatient's homeOutcomesResidents
2014
Variation in transfusion rates within a single institution: Exploring the effect of differing practice patterns on the likelihood of blood product transfusion in patients undergoing cardiac surgery
Cote C, MacLeod J, Yip A, Ouzounian M, Brown C, Forgie R, Pelletier M, Hassan A. Variation in transfusion rates within a single institution: Exploring the effect of differing practice patterns on the likelihood of blood product transfusion in patients undergoing cardiac surgery. Journal Of Thoracic And Cardiovascular Surgery 2014, 149: 297-302. PMID: 25300883, DOI: 10.1016/j.jtcvs.2014.09.004.Peer-Reviewed Original ResearchConceptsRate of perioperative transfusionPerioperative transfusion ratesPerioperative transfusionTransfusion rateCardiac surgeryPractice patternsIntraoperative variablesPredictors of perioperative transfusionPredictors of blood transfusionOverall transfusion rateBlood product transfusionRisk-adjusted effectYear of procedureProduct transfusionBlood transfusionClinical predictorsIndependent predictorsClinical characteristicsClinical factorsTransfusionPatientsStudy populationSurgeryMultivariable regression modeling techniquesNonclinical factors
2010
Angiogenic Effects Despite Limited Cell Survival of Bone Marrow-Derived Mesenchymal Stem Cells under Ischemia
Hoffmann J, Glassford A, Doyle T, Robbins R, Schrepfer S, Pelletier M. Angiogenic Effects Despite Limited Cell Survival of Bone Marrow-Derived Mesenchymal Stem Cells under Ischemia. The Thoracic And Cardiovascular Surgeon 2010, 58: 136-142. PMID: 20379963, DOI: 10.1055/s-0029-1240758.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenic ProteinsAnimalsApoptosisCapillariesCell HypoxiaCell ProliferationCell SurvivalCells, CulturedDisease Models, AnimalFemaleFibroblastsGreen Fluorescent ProteinsHindlimbIschemiaLuciferases, FireflyMaleMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMiceMice, TransgenicMuscle, SkeletalNecrosisNeovascularization, PhysiologicTime FactorsConceptsMarrow-derived mesenchymal stem cellsMarrow-derived mesenchymal stem cell transplantationMesenchymal stem cellsProliferation of MSCsMurine ischemic limbsOcclusive arterial diseaseMSC groupMarrow-derived mesenchymal stem cell survivalVessel densityArtery diseaseBone marrow-derived mesenchymal stem cellsIn vitro cell viabilityStem cellsHypoxic conditions in vitroFiber ratioComparison to fibroblastsCapillary to muscle fiber ratioCell deliveryClinically relevant toolSecrete angiogenic factorsHypoxic conditionsLimited cell survivalHindlimb ischemia modelFVB miceMuscle fiber ratio
2007
In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure
Sheikh A, Chun H, Glassford A, Kundu R, Kutschka I, Ardigo D, Hendry S, Wagner R, Chen M, Ali Z, Yue P, Huynh D, Connolly A, Pelletier M, Tsao P, Robbins R, Quertermous T. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. AJP Heart And Circulatory Physiology 2007, 294: h88-h98. PMID: 17906101, PMCID: PMC2570026, DOI: 10.1152/ajpheart.00935.2007.Peer-Reviewed Original ResearchMeSH KeywordsAdipokinesAnimalsApelinApelin ReceptorsBasic Helix-Loop-Helix Transcription FactorsCarrier ProteinsCell HypoxiaCells, CulturedCoronary VesselsDisease Models, AnimalEndothelial CellsFemaleGene Expression ProfilingGenes, ReporterHeart FailureHumansHypoxiaHypoxia-Inducible Factor 1, alpha SubunitIntercellular Signaling Peptides and ProteinsLac OperonLigationLungMiceMice, TransgenicMyocardial IschemiaMyocardiumPromoter Regions, GeneticQuadriceps MuscleReceptors, G-Protein-CoupledRNA, MessengerSignal TransductionTime FactorsTransfectionUp-RegulationConceptsApelin-APJ pathwayHeart failureCardiac failureApelin expressionCultured endothelial cells in vitroConditions associated with heart failureLocalization of apelinRegulation of cardiovascular functionG protein-coupled receptor APJIschemic heart failureIschemic cardiac failureSystemic vascular resistanceEndothelial cells in vitroLocal tissue hypoxiaSystemic hypoxic exposureNitric oxide-dependent signalingCells in vitroRegulating cardiovascular homeostasisVasopressin pathwayInotropic effectCardiac contractilityVascular resistanceMurine modelLigand apelinMyocardial injury
2005
Thoratec Ventricular Assist Devices in Pediatric Patients: Update on Clinical Results
Reinhartz O, Hill J, Al-Khaldi A, Pelletier M, Robbins R, Farrar D. Thoratec Ventricular Assist Devices in Pediatric Patients: Update on Clinical Results. ASAIO Journal 2005, 51: 501-503. PMID: 16322705, DOI: 10.1097/01.mat.0000178214.95010.c0.Peer-Reviewed Original ResearchConceptsThoratec ventricular assist deviceCongenital heart diseaseBody surface areaVentricular assist deviceAcute myocarditisHeart diseasePediatric patientsEnd-stage congenital heart diseaseIncidence of congenital heart diseaseOverall survival to transplantationMean body surface areaSurvival to transplantYears of ageMechanical circulatory supportClinical resultsClinical challengeAssist deviceSurvival ratePatientsCirculatory supportAverage durationSmall childrenMean weightThoratecCardiomyopathy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply